RESEARCH NOTE

REVISED Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection [version 2; peer review: 2 approved]

Veljko Veljkovic ¹, Slobodan Paessler^{2,3}

¹Biomed Protection, Galveston, TX, USA

²Department of Pathology, Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA

³Galveston National Laboratory, Institute for Human Infectious and Immunity, Galveston, TX, USA

v2 First published: 18 Feb 2016, 5:190
<https://doi.org/10.12688/f1000research.8102.1>

Latest published: 23 Mar 2016, 5:190
<https://doi.org/10.12688/f1000research.8102.2>

Abstract

The *in silico* analysis shows that the envelope glycoproteins E of Zika viruses (ZIKV) isolated in Asia, Africa and South and Central America encode highly conserved information determining their interacting profile and immunological properties. Previously it was shown that the same information is encoded in the primary structure of the hemagglutinin subunit 1 (HA1) from pdmH1N1 influenza A virus. This similarity suggests possible repurposing of the seasonal influenza vaccine containing pdmH1N1 component for prevention of the ZIKV infection.

Keywords

Zika virus , vaccine , influenza virus , vaccine repurposing , in silico analysis , hemagglutinin , envelope glycoprotein E , informational spectrum method

This article is included in the **Emerging Diseases and Outbreaks** gateway.

Open Peer Review

Approval Status

	1	2
version 2 (revision) 23 Mar 2016	 view	
version 1 18 Feb 2016	 view	 view

1. **Patrizio Arrigo**, National Research Council, Genoa, Italy

2. **Heinz Kohler**, University of Kentucky, Lexington, USA

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Veljko Veljkovic (veljkve@gmail.com)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2016 Veljkovic V and Paessler S. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Veljkovic V and Paessler S. **Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection [version 2; peer review: 2 approved]** F1000Research 2016, 5:190 <https://doi.org/10.12688/f1000research.8102.2>

First published: 18 Feb 2016, 5:190 <https://doi.org/10.12688/f1000research.8102.1>

REVISED Amendments from Version 1

Figure 2 and Figure 3 in the new version of the article are extended with data which additionally support informational similarity between the E protein from Zika virus and HA1 from the pdmH1N1 influenza virus.

See referee reports

Introduction

The recent pandemic of the pdmH1N1 influenza virus and epidemic of the Ebola virus in West Africa showed a lack of preparedness to adequately respond to emerging infectious diseases with potential catastrophic consequences. One of the main obstacles to a fast and efficient response to emerging new infectious disease is insufficient knowledge of the biological, immunological and pathogenic properties of new pathogens and a lack of an appropriate experimental system for testing drugs and vaccines. The new emergence of the ZIKV showed that despite significant progress in molecular biology, biochemistry, immunology, medicine and pharmacology which allows better understanding, prevention and therapy of infectious diseases, the world once again is not prepared for early and decisive action which would prevent hundreds of unnecessary cases of ZIKV infections and potential congenital abnormalities in newborns caused by this virus.

Previously, at the beginning of the HIV epidemic¹, and recently during the swine flu pandemic² and Ebola epidemic in West Africa³, we demonstrated that the bioinformatics tool which is based on the informational spectrum method (ISM)⁴ can give some useful information about the host-pathogen interaction and help in selection of drug and vaccine candidates. An essential advantage of ISM over other bioinformatics approaches is in the use of DNA and protein sequences as the only input information which allows analysis of new pathogens. Because data about the sequencing of new pathogens usually are available at the beginning of the outbreaks, the ISM analysis can start immediately and provide some information which could accelerate development of vaccines and drugs.

The ZIKV, native to parts of Africa and Asia, has for the first time been introduced into the Americas. The ZIKV epidemic in Brazil currently is estimated at 440000–1300000 cases, and in February 2016 it has spread to other Latin-American countries, the USA and Europe ([http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(16\)00014-3.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)00014-3.pdf)), threatening to become a pandemic. Recently, the World Health Organization (WHO) declared an international public health emergency (<http://www.who.int/mediacentre/news/statements/2016/emergency-committee-zika-microcephaly/en/>). There is no vaccine against the virus or any antiviral treatment.

Here we analyzed ZIKV E proteins using ISM. Results of this *in silico* analysis revealed that these viral proteins encode the highly conserved information which determines their interacting profile and immunological properties. Previously, we reported that the human interacting profile of HA1 from pdmH1N1 influenza viruses is characterized by the same information². This result suggests possible repurposing of the seasonal influenza vaccine containing pdmH1N1 for prevention of ZIKV infection.

Material and methods**Sequences**

All sequences of the ZIKV E protein are taken from the NCBI databank (<http://www.ncbi.nlm.nih.gov/nucore/?term=zika>) and are given in **Dataset 1** (accessions: KU312314, KU312315, KU312313, KU312312, KJ776791, KJ634273, KF993678, JN860885, EU545988, HQ234499, KF268950, KF268948, KF268949, AY632535, LC002520, DQ859059, HQ234501, HQ234500, FSS13025, AHL43505, AHL43503, AHL43502, AMA12087). Sequences for HA1 from influenza viruses were taken from the GISAID database (<http://platform.gisaid.org>) and are given in **Dataset 2** (accessions: EPI705910, EPI696955).

Dataset 1. Sequences of the ZIKV E protein taken from the NCBI databank (accessions: KU312314, KU312315, KU312313, KU312312, KJ776791, KJ634273, KF993678, JN860885, EU545988, HQ234499, KF268950, KF268948, KF268949, AY632535, LC002520, DQ859059, HQ234501, HQ234500, FSS13025, AHL43505, AHL43503, AHL43502, AMA12087)

<http://dx.doi.org/10.5256/f1000research.8102.d114325>

Dataset 2. Sequences of HA of A/California/07/2009(H1N1) and HA of A/Switzerland/9715293/2013(H3N2) taken from the GSAID database (accessions: EPI705910, EPI696955)

<http://dx.doi.org/10.5256/f1000research.8102.d114326>

Informational spectrum method

The ISM is a virtual spectroscopy technique, developed for the study of protein-protein interactions. The physical and mathematical base of ISM was described in detail elsewhere (5 and references therein), and here we will only in brief present this bioinformatics method.

The ISM technique is based on a model of the primary structure of a protein using a sequence of numbers, by assigning to each amino acid the correspondence value of the electron ion interaction potential (EIIP; L 0.0000, I 0.0000, N 0.0036, G 0.0050, V 0.0057, E 0.0058, P 0.0198, H 0.0242, K 0.0371, A 0.0373, Y 0.0516, W 0.0548, Q 0.0761, M 0.0823, S 0.0829, C 0.0829, T 0.0941, F 0.0946, R 0.0959, D 0.1263). The EIIP values are in Rydbergs (Ry).

The obtained numerical sequence is then subjected to a discrete Fourier transformation which is defined as follows:

$$X(n) = \sum x(m)e^{-j(2/N)nm}, n = 1, 2, \dots, N/2 \quad (1)$$

where $x(m)$ is the m -th member of a given numerical series, N is the total number of points in this series, and $X(n)$ are discrete Fourier transformation coefficients. These coefficients describe the amplitude, phase and frequency of sinusoids, which comprised the original signal. Relevant information encoded in the primary structure is presented in an energy density spectrum which is defined as follows:

$$S(n) = X(n)X^*(n) = |X(n)|^2, n = 1, 2, \dots, N/2. \quad (2)$$

In this way, sequences are analyzed as discrete signals. It is assumed that their points are equidistant with the distance $d = 1$. The maximal

frequency in a spectrum defined as above is $F = 1/2d = 0.5$. The frequency range is independent of the total number of points in the sequence. The total number of points in a sequence influences only the resolution of the spectrum. The resolution of the N-point sequence is $1/n$. The n-th point in the spectral function corresponds to a frequency $f(n) = nf = n/N$. Thus, the initial information defined by the sequence of amino acids can now be presented in the form of the informational spectrum (IS), representing the series of frequencies and their amplitudes.

The IS frequencies correspond to the distribution of structural motifs with defined physicochemical properties determining a biological function of a protein. When comparing proteins, which share the same biological or biochemical function, the ISM technique allows detection of code/frequency pairs which are specific for their common biological properties, or which correlate with their specific interaction. These common informational characteristics of sequences are determined by the cross-spectrum (CS) which is obtained by the following equation:

$$C(j) = \prod S(i,j) \quad (3)$$

where $\prod(i,j)$ is the j-th element of the i-th power spectrum and $C(j)$ is the j-th element of CS. Peak frequencies in CS represent the common information encoded in the primary structure of analyzed sequences. This information corresponds to the mutual interaction between analyzed proteins or their interaction with the common interactor.

Results and discussion

The envelope glycoprotein (protein E) which mediates the virus cell entry is highly conserved and virtually identical in all ZIKV isolated during 2015 in countries of Central and South America. **Figure 1A** shows the IS of ZIKV E isolated in 2015 in Brazil (AMA12087) which is characterized by a dominant peak at frequency $F(0.295)$. **Figure 1B** shows the CIS of protein E from ZIKV isolated between 1968 and 2015 in diverse countries of Asia and Africa (**Dataset 1**). This CIS contains only one dominant peak at frequency $F(0.295)$. This result suggests that all analyzed ZIKV E encode the same highly conserved information which is represented by the IS frequency $F(0.295)$. According to the ISM concept⁶⁻⁹, this information determines the interacting profile of ZIKV E.

Previously, it has been shown that frequency $F(0.295)$ characterizes the human interacting profile of pdmH1N1 HA1 (**Figure 2C**)². It has also been shown that antigens which share a common frequency component in their IS are immunologically cross-reactive (10 and references therein). Presence of the frequency component $F(0.295)$ in ZIKV E and pdmH1N1 HA indicates that antibodies elicited by this protein of influenza virus could affect interaction between ZIKV E and host proteins. We compared the IS of ZIKV E and HA1 from A/California/07/2009(H1N1) and A/Switzerland/9715293/2013(H3N2) viruses, which are components of the 2015/2016 seasonal influenza vaccine. Results given in **Figure 2** and **Figure 3A** show that ZIKV E and A/California/07/2009(H1N1) encode the common information represented in their IS with the dominant peak at frequency $F(0.295)$. As can be seen in **Figure 3B & 3C**,

this frequency component is not present in the IS of A/Switzerland/9715293/2013(H3N2) HA1. These results indicate that antibodies elicited by the vaccine virus A/California/07/2009(H1N1) could affect interaction between ZIKA E and host proteins mediating virus cell entry.

Conclusions

The presented results of the *in silico* analysis of ZIKV E and host factors mediating viral infection suggest that the seasonal influenza vaccines containing pdmH1N1 as a component, could protect to some extent against the ZIKV infection. Because of the lack of prevention and therapy of the ZIKV disease, in a situation when

Figure 1. (A) The informational spectrum of ZIKV E protein. (B) The consensus informational spectrum of protein E from ZIKV isolated in Asia, Africa and South/Central America.

Figure 2. (A) The informational spectrum of ZIKV E protein. (B) The informational spectrum of HA1 from A/California/07/2009(H1N1) influenza virus. (C) The consensus informational spectrum of HA1 from pdmH1N1².

Figure 3. (A) The cross-spectrum of ZIKV E protein and HA1 from A/California/07/2009(H1N1) influenza virus. (B) The cross-spectrum of ZIKV E protein and HA1 from A/Switzerland/9715293/2013(H3N2) influenza virus. (C) The cross-spectrum of HA1 from A/California/07/2009(H1N1) and A/Switzerland/9715293/2013(H3N2) influenza viruses.

the ZIKV infection is explosively spreading, this possible safe and inexpensive solution is worth being seriously considered.

Data availability

F1000Research: Dataset 1. Sequences of the ZIKV E protein taken from the NCBI databank (accessions: KU312314, KU312315, KU312313, KU312312, KJ776791, KJ634273, KF993678, JN860885, EU545988, HQ234499, KF268950, KF268948, KF268949, AY632535, LC002520, DQ859059, HQ234501, HQ234500, FSS13025, AHL43505, AHL43503, AHL43502, AMA12087), [10.5256/f1000research.8102.d114325](https://doi.org/10.5256/f1000research.8102.d114325)¹¹

F1000Research: Dataset 2. Sequences of HA of A/California/07/2009(H1N1) and HA of A/Switzerland/9715293/2013(H3N2) taken

from the GSAID database (accessions: EPI705910, EPI696955), [10.5256/f1000research.8102.d114326](https://doi.org/10.5256/f1000research.8102.d114326)¹²

Author contributions

Conceived and designed the study: VV SP. Analyzed the data: VV. Wrote the paper: VV SP.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Veljković V, Metlas R: **Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein.** *Cancer Biochem Biophys.* 1988; 10(2): 91–106.
[PubMed Abstract](#)
2. Veljkovic V, Niman HL, Glisic S, *et al.*: **Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor.** *BMC Struct Biol.* 2009; 9: 62.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Veljkovic V, Glisic S, Muller CP, *et al.*: **In silico analysis suggests interaction between Ebola virus and the extracellular matrix.** *Front Microbiol.* 2015; 6: 135.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Veljković V, Cosić I, Dimitrijević B, *et al.*: **Is it possible to analyze DNA and protein sequences by the methods of digital signal processing?** *IEEE Trans Biomed Eng.* 1985; 32(5): 337–341.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Veljkovic N, Glisic S, Prljic J, *et al.*: **Discovery of new therapeutic targets by the informational spectrum method.** *Curr Protein Pept Sci.* 2008; 9(5): 493–506.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Veljkovic V, Veljkovic N, Muller CP, *et al.*: **Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control.** *BMC Struct Biol.* 2009; 9: 21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Perovic VR, Muller CP, Niman HL, *et al.*: **Novel phylogenetic algorithm to monitor human tropism in Egyptian H5N1-HPAIV reveals evolution toward efficient human-to-human transmission.** *PLoS One.* 2013; 8(4): e61572.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Schmier S, Mostafa A, Haarmann T, *et al.*: **In Silico Prediction and Experimental Confirmation of HA Residues Conferring Enhanced Human Receptor Specificity of H5N1 Influenza A Viruses.** *Sci Rep.* 2015; 5: 11434.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Veljkovic V, Paessler S, Glisic S, *et al.*: **Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic.** *Front Microbiol.* 2015; 6: 1456.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Veljkovic V, Glisic S, Veljkovic N, *et al.*: **Influenza vaccine as prevention for cardiovascular diseases: possible molecular mechanism.** *Vaccine.* 2014; 32(48): 6569–6575.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Veljkovic V, Paessler S: **Dataset 1 in: Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection.** *F1000Research.* 2016.
[Data Source](#)
12. Veljkovic V, Paessler S: **Dataset 2 in: Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection.** *F1000Research.* 2016.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 27 April 2016

<https://doi.org/10.5256/f1000research.9037.r13043>

© 2016 Arrigo P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patrizio Arrigo

Institute for Macromolecular Studies, National Research Council, Genoa, Italy

I've checked the second revised version and it agrees with my suggestions. I guess it can now be indexed

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 14 March 2016

<https://doi.org/10.5256/f1000research.8717.r12533>

© 2016 Kohler H. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Heinz Kohler

Department of Microbiology and Immunology, University of Kentucky, Lexington, KY, USA

This manuscript provides important information on the envelope of Zika virus that will help to produce a vaccine.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 03 March 2016

<https://doi.org/10.5256/f1000research.8717.r12535>

© 2016 Arrigo P. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patrizio Arrigo

Institute for Macromolecular Studies, National Research Council, Genoa, Italy

The paper summarizes an application of well established and efficient ISM method to compare ZIKA and H1N1. I would like to underline two points that I guess to be better describe. I suggest that Figure 2 can contain also the consensus spectrum as Figure 1.

The second point is the description of Figure 3 in the result section. I guess that the authors could extended the illustration of the differences of the cross-spectrum. These differences are very interesting data for discrimination. Another small remark is about the aim of the paper. The authors suggest a 'repositioning' of H1N1 vaccine if it is possible I would like to ask them if they have considered the possibility to elicit unfavourable effect of cross reactivity with the consequence to reduce the vaccine efficiency.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research